Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

BERLIN--(BUSINESS WIRE)--Bayer's Pharmaceutical Division is set to embark on its next phase of growth, reshaping its executive Leadership Team to become more mission-centric and value focused. The company has been making important strides in strengthening its development portfolio and extending its capabilities through collaborations and acquisitions into breakthrough therapeutic fields such as gene therapies and cell therapies. As a next step, Bayer's Pharmaceutical Division is focusing on ren.

Bayer Pharmaceuticals streamlines Leadership Team for next phase of growth

Thermo Fisher Scientific

BERLIN & CARLSBAD, Calif.--(BUSINESS WIRE)--Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer's growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time. The CDx will be developed using Thermo Fisher's Oncomine Dx Express Test* on the Ion Torrent Genexus Dx System*, a fully i.

Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines

BERLIN--(BUSINESS WIRE)--Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo. In this study, elinzanetant successfully met the primary endpoint demonstrating statistically significant reduction in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to week 12 compared to placebo. The long-term safety profile observed.

Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer's elinzanetant

Bayer said on Tuesday that it would request regulatory approval for its menopause drug after the daily pill was shown to ease hot flashes in a third late-stage trial, providing some relief for its pharmaceuticals unit that is reeling from a recent development setback.

Bayer to seek approval for menopausal relief drug after third trial win

Not intended for UK Media Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development, further strengthening Bayer's precision oncology development portfolio Co-development of a novel target identification platform leveraging multimodal patient data and industry-leading AI/ML algorithms Development of computational pathology algorithms connecting baseline data such as molecular tumor profiles with patient outcome to enable better patient identification, stratification, and selection for clinical trials BERLIN, March 14, 2024 (GLOBE NEWSWIRE) -- Bayer and Aignostics GmbH today announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world's leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.

Bayer and Aignostics to collaborate on next generation precision oncology

Top three Bayer shareholder Harris Associates on Thursday came out in strong support of the drugmaker's strategy to suspend work on a separation of the diversified group and to focus on improving the company's operating performance.

Major Bayer shareholder Harris backs CEO's focus on internal restructuring

Bayer (ETR: BAYN) share price has been in a strong freefall and it sits at its lowest level in almost 20 years. The stock crashed to a low of €25.57 on Thursday, making it the worst-performing company in the DAX index.

Bayer share price is in a freefall: is it safe to buy the dip?

Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.

Bayer (BAYRY) Q4 Earnings Top, Crop Science Unit Drives Revenues

WHIPPANY, N.J.--(BUSINESS WIRE)--Today Bayer won its third consecutive trial victory when a jury reached a defense verdict in its most recent trial – the Kline Roundup™ product liability trial – before Judge Ann Butchart in Philadelphia. Separately, Plaintiffs voluntarily dismissed with prejudice the Meyer case which was at trial in the Superior Court of California for Sonoma County. These follow the defense verdict in Cody in Conway County, Arkansas, as well as a mistrial in Cloud in Delaware.

Bayer Wins Third Consecutive Trial Victory

Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.

Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug

Bayer AG (OTCPK:BAYZF) Q4 2023 Earnings Conference Call March 5, 2024 3:30 AM ET Company Participants Michael Preuss - Head, Communications, Government Relations and Corporate Brand Julio Triana - Head, Commercial Operations Region International William Anderson - Chairman & CEO Heike Prinz - Chief Talent Officer & Labor Director Heiko Schipper - President, Consumer Health Division Wolfgang Nickl - CFO Stefan Oelrich - Head, Pharmaceuticals Division Rodrigo Santos - President, Crop Science Division Conference Call Participants Tim Loh - Bloomberg Aimee Donnellan - Reuters Kevin Grogan - Scrip Olaf Storbeck - Financial Times Isabella Bufacchi - Il Sole Patricia Weiss - Reuters Ludwig Burger - Reuters Jonas Jansen - Frankfurter Allgemeine Zeitung Reynald Castañeda - Endpoint News Stephen Wilmot - The Wall Street Journal Michael Preuss Hello, everyone, and many thanks for joining us today for our strategic update and 2024 annual press conference. Thanks very much for your time and your interest in Bayer.

Bayer AG (BAYZF) Q4 2023 Earnings Call Transcript

Bayer said on Monday it acquired the exclusive marketing rights for Europe for a new drug that is under regulatory review to treat a rare, potentially fatal heart disease for up to $310 million upfront.

Bayer purchases heart drug for up to $310 mln

BridgeBio Pharma Inc

BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday.

BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe

Vivendi SE

The Stoxx 600 index will be in the spotlight this week as the European Central Bank (ECB) delivers its second interest rate decision of the year. The index, which tracks the biggest European companies, surged to a record high of €497, which was about 30% above its lowest point in December 2022.

Euro Stoxx 600 sits at ATH ahead of Bayer, Pirelli, Vivendi earnings

Bayer is not planning to announce a split of its company at its Capital Markets Day next week, Handelsblatt said on Friday, citing people familiar with the matter.

Bayer not planning to announce split of company at Capital Markets Day - HB

Bayer said that the head of its consumer health division, Heiko Schipper, would be replaced by Julio Triana, currently the unit's head of commercial operations region international.

Head of Bayer's consumer unit Schipper to be replaced by Julio Triana

Bayer may have to ask shareholders for fresh capital to shore up its finances even after the debt-laden German drugmaker slashed dividends last week in its latest effort to get wiggle room, analysts said.

Bayer investors weigh need for cash call amid stifling debt

BERLIN--(BUSINESS WIRE)--Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2.

Bayer Receives U.S. FDA Breakthrough Therapy Designation for BAY 2927088 for Non-Small Cell Lung Cancer Harboring HER2 Activating Mutations

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Fund, a philanthropic arm of Bayer in the U.S., is proud to announce that it has provided a total of $4.7 million in grant funding, spanning across 500 organizations, in the second half of 2023. This latest round of grants raised Bayer Fund's total giving to more than $12.1 million for the year across 2,300 charitable and nonprofit organizations supporting Food & Nutrition, Science, Technology, Engineering and Mathematics (STEM) Education and Health &a.

Bayer Fund Awards More than $12.1M to U.S. Nonprofit Organizations in 2023, Following Latest Round of Grants Totaling $4.7M

Bayer recently cut its dividend by more than 90%, resulting in a dividend yield of less than 1%. The company's valuation actually rose after the dividend cut, indicating investor approval.

Bayer: Long-Term Upside After The Dividend Cut

Bayer announced plans to cut its dividend a staggering 95% over the next three years as it looks to recover from debt associated with its acquisition of Monsanto Co., which thrust the German corporation to the center of multiple lawsuits involving Roundup weed killer.

Bayer slashes dividend by 95% as company faces wave of litigation over Roundup weed killer

Bayer (BAYRY) announced plans to cut dividends to pay out only the legally required minimum for three years in the wake of high debt and increasing legal costs.

Bayer (BAYRY) Intends to Slash Dividends Amid Challenges

BERLIN--(BUSINESS WIRE)--Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT). The results of this study might provide evidence of anti-α2ap antibody's potential as a treatment option in indications of high medical relevance. "We are excited to advance our anti-α2ap antibody to the next stage of clinical development in patients with d.

Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis

Bayer's CEO said on Friday that the healthcare and crop chemicals group continues to firmly back its glyphosate weedkiller even after a recent courtroom loss in U.S. litigation over an alleged carcinogenic effect.

Bayer CEO says company stands behind glyphosate

A U.S. appeals court on Monday refused to dismiss a lawsuit claiming that Bayer AG's Roundup weedkiller caused cancer, the latest setback in the company's efforts to fend off thousands of similar lawsuits carrying potentially billions of dollars in damages.

News for Bayer AG Stock (BAYRY)